Avanir Targets Impax Over Generic Nuedexta Plans

Law360, New York (October 9, 2012, 1:38 PM EDT) -- Avanir Pharmaceuticals Inc. on Monday sued rival Impax Laboratories Inc. in Delaware federal court, claiming Impax's plans to make a generic version of involuntary-emotion drug Nuedexta infringe one of its patents.

According to Aliso Viejo, Calif.-based Avanir’s complaint, Impax’s plans to make a generic version of Nuedexta — a combination of the drugs dextromethorphan and quinidine, used to treat a neurological condition involving involuntary laughing or crying episodes — infringes U.S. Patent Number 8,227,484, one of several patents covering the drug.

“Avanir will be substantially and...
To view the full article, register now.